Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Increases By 15.2%

Bionano Genomics, Inc. (NASDAQ:BNGOGet Free Report) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 4,770,000 shares, an increase of 15.2% from the August 15th total of 4,140,000 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is presently 4.3 days. Approximately 15.7% of the company’s shares are short sold.

Institutional Trading of Bionano Genomics

Several large investors have recently made changes to their positions in BNGO. Merit Financial Group LLC acquired a new stake in Bionano Genomics in the 1st quarter worth approximately $28,000. Bayesian Capital Management LP acquired a new position in Bionano Genomics in the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC bought a new position in Bionano Genomics in the 1st quarter worth $34,000. Osaic Holdings Inc. lifted its position in Bionano Genomics by 5.1% during the 2nd quarter. Osaic Holdings Inc. now owns 61,649 shares of the company’s stock worth $38,000 after acquiring an additional 2,984 shares during the last quarter. Finally, Brinker Capital Investments LLC bought a new stake in Bionano Genomics during the first quarter valued at about $41,000.

Wall Street Analysts Forecast Growth

Separately, BTIG Research increased their target price on shares of Bionano Genomics to $10.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th.

View Our Latest Analysis on BNGO

Bionano Genomics Stock Performance

Shares of NASDAQ BNGO remained flat at $3.00 during trading hours on Tuesday. The company had a trading volume of 504,305 shares, compared to its average volume of 882,473. The company’s 50 day moving average price is $5.27 and its 200-day moving average price is $7.31. Bionano Genomics has a 1-year low of $2.93 and a 1-year high of $30.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.69 and a current ratio of 3.66.

Bionano Genomics (NASDAQ:BNGOGet Free Report) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.34). The business had revenue of $8.66 million for the quarter, compared to analyst estimates of $8.11 million. Bionano Genomics had a negative return on equity of 59.97% and a negative net margin of 464.96%. On average, research analysts predict that Bionano Genomics will post -3.5 earnings per share for the current fiscal year.

About Bionano Genomics

(Get Free Report)

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.

Further Reading

Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with's FREE daily email newsletter.